The Ministry of Health, Labor and Welfare (MHLW) appears to be ready to begin post-launch drug price adjustments based on cost-effectiveness assessments (CEAs) for the first time since the system was introduced in April 2019. As price tweaks will be…
HOME > ORGANIZATION
ORGANIZATION
- 3 Indicted Wholesalers Now Barred from National Hospital Organization Bids, Others Following Suit
December 21, 2020
- 3 Pharma Groups Rap Off-Year Drug Re-Pricing Plan; Generic Industry Frets Impact on Stable Supplies
December 21, 2020
- AbbVie’s James Feliciano to Take Helm at PhRMA Japan in January
December 18, 2020
- Savings from Off-Year Re-Pricing Should Go Towards Physician Fees: JMA Chief
December 17, 2020
- Tokushukai Switching from Kobayashi Kako Products after Tainted Itraconazole Issue
December 16, 2020
- 3 Indicted Wholesalers Barred from JCHO Bids for 2 Years: Bid-Rigging Scandal
December 14, 2020
- Pharmacist Group Chief Appalled at Itraconazole Recalls; 84 Cases of Health Damages Reported
December 10, 2020
- GHIT Fund to Bankroll 230 Million Yen for 4 Projects to Develop New Therapies for Chagas Disease, Malaria
December 9, 2020
- NBI President Yoshiaki Aono Elected as New EFPIA Japan Vice Chair
December 7, 2020
- JPMA Girding for Culmination in Off-Year Re-Pricing, Tax Debates Late November-Early December: Exec
November 20, 2020
- EFPIA Japan Chief Frets Declining Priority for Japan Market since 2018 Pricing Overhaul
November 19, 2020
- Active Hep C Treatment Estimated to Save 1.3 Trillion Yen in Healthcare Costs in 20 Years: INES
November 18, 2020
- JPMA Sorts Out Challenges for Remote Clinical Trial to Promote Its Introduction in Japan
November 9, 2020
- Raise Copay Rates to 20% for Seniors Over 75 ASAP: 5 Insurers
November 5, 2020
- Sales Reps in Japan Decrease to 57,158 in FY2019, Down for 6 Years Running: Survey
November 5, 2020
- PhRMA Makes 3-Pronged Proposal to Japan Govt, Calls for Fueling Innovation, Investment, and Digitalization
October 29, 2020
- Japan Trade Groups Step Up Lobbying Campaigns as Diet Convenes, Renew Call for “Cautious Approach” to Off-Year Re-Pricing
October 27, 2020
- FPMAJ Urges Drug Makers to Ensure Stable Supply of Newly Listed Products
October 16, 2020
- COVID-19 Affecting Reimbursement Fee Incentive for Biosimilars: JPA Exec
October 16, 2020
- Take COVID as Opportunity to “Reset” Overdependence on Drug Price Cuts: PhRMA Chief
October 12, 2020
ページ
Biogen’s controversial Alzheimer’s drug aducanumab was filed for Japanese regulatory approval in December. If approved, it will be the first…
Japan’s key reimbursement policy panel on December 20 approved an outline of its FY2020 drug pricing reform next April, with…
The Ministry of Health, Labor and Welfare (MHLW) on November 27 added to the NHI price list Japan’s first biosimilars of Avastin (bevacizumab), Nesp (darbepoetin alfa), and Forteo (teriparatide). The NHI prices of first biosimilars are set at 70% of…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…
After decades in recruitment, I say from experience that there’s a particular way to attract candidates to a given role. Do it right, and you’ll have talent chasing you. Get it wrong, and you’ll be left listening to the crickets…